BioMarin Pharmaceutical (BMRN) said Friday that it has agreed to acquire Inozyme Pharma (INZY) at $4 per share in cash for a total price of $270 million.
The biotech company said the deal is expected to close in Q3, which is contingent on regulatory approval, completion of a tender offer, and other customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.